PBMs oppose US FTC request for January 2026 admin trial in insulin antitrust case
( March 11, 2025, 16:30 GMT | Official Statement) -- MLex Summary: Caremark Rx, Express Scripts, OptumRx and other firms facing antitrust claims from the US Federal Trade Commission over insulin prices told an agency administrative law judge that delaying an evidentiary hearing in the case to Jan. 27, 2026 would "greatly prejudice" the companies and be "unprecedented under the Commission's current rules."See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.